MedPath

Product Performance of a New Silicone Hydrogel Contact Lens

Not Applicable
Completed
Conditions
Myopia
Interventions
Device: kalifilcon A
Device: delefilcon A
Device: senofilcon A
Registration Number
NCT04901897
Lead Sponsor
Bausch & Lomb Incorporated
Brief Summary

The objective of this study is to evaluate the product performance of kalifilcon A, compared to the Johnson \& Johnson Acuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens and Alcon DAILIES TOTAL1® (delefilcon A) daily disposable contact lenses when worn by current soft contact lens wearers on a daily disposable wear basis.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
805
Inclusion Criteria
  • 18 to 40 years old on the date the ICF is signed and have capacity to provide voluntary informed consent.
  • myopic and require lens correction from -0.50 to -6.00 Diopter (D) with 0.25 D steps, in each eye.
  • correctable through spherocylindrical refraction and with soft spherical contact lenses to 32 letters (0.3 logarithm of the minimum angle of resolution [logMAR]) or better (2 meters distance, high-contrast chart) in each eye.
  • free of any anterior segment disorders.
  • adapted soft contact lens wearers and willing to wear their study lenses for at least 8 hours per day on a daily disposable wear basis for approximately 2 weeks.
  • access to internet connection and personal email to send/receive emails.
  • habitually wear either Alcon's Air Optix Aqua, Air Optix with HydraGlyde, Air Optix Night & Day, Bausch + Lomb's PureVision 2, Bausch + Lomb ULTRA, CooperVision's Biofinity, Johnson & Johnson Acuvue Oasys® with HydraClear™, or Acuvue Vita soft contact lenses.
Exclusion Criteria
  • participating in any drug or device clinical investigation within 2 weeks prior to entry into this study (Screening/Dispensing Visit) and/or during the period of study participation.
  • have worn gas permeable (GP) contact lenses within the last 30 days or who have worn polymethylmethacrylate (PMMA) lenses within the last three months.
  • have any systemic or ocular disease currently affecting ocular health in the Investigator's opinion may have an effect on ocular health during the course of the study.
  • using any systemic, topical or topical ocular medications that will in the Investigator's opinion, affect ocular physiology or lens performance.currently wear daily disposable, monovision, multifocal, or toric contact lenses.
  • refractive astigmatism of greater than 0.75 D in either eye.
  • anisometropia (spherical equivalent) of greater than 2.00 D.
  • amblyopic.
  • have had any corneal surgery (e.g., refractive surgery).

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
kalifilcon Akalifilcon Akalifilcon A daily disposable contact lens
delefilcon Adelefilcon ADAILIES TOTAL1® (delefilcon A) daily disposable contact lenses
senofilcon Asenofilcon AAcuvue Oasys® 1-Day with HydraLuxe™ (senofilcon A) daily disposable contact lens
Primary Outcome Measures
NameTimeMethod
Percentage of Participants in the Test Lens Group Agreeing With the Statement "Are Comfortable Throughout the Day"2 Week Follow up
Percentage of Participants in the Test Lens Group Agreeing With the Statement "Provide Clear Vision Throughout the Day"2 Week Follow up
Mean Change in logMAR Contact Lens Visual AcuityBaseline, 2 Week Follow up

logMAR is the logarithm of the minim angle of resolution

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (35)

Bausch Site 431

🇺🇸

Scottsdale, Arizona, United States

Bausch Site 406

🇺🇸

Azusa, California, United States

Bausch Site 430

🇺🇸

Los Angeles, California, United States

Bausch Site 432

🇺🇸

Sunnyvale, California, United States

Bausch Site 409

🇺🇸

Torrance, California, United States

Bausch Site 415

🇺🇸

Jacksonville, Florida, United States

Bausch Site 434

🇺🇸

Jacksonville, Florida, United States

Bausch Site 405

🇺🇸

Sarasota, Florida, United States

Bausch Site 401

🇺🇸

'Aiea, Hawaii, United States

Bausch Site 412

🇺🇸

Decatur, Georgia, United States

Bausch Site 421

🇺🇸

Sterling Heights, Michigan, United States

Bausch Site 413

🇺🇸

Portland, Maine, United States

Bausch Site 429

🇺🇸

Edina, Minnesota, United States

Bausch Site 422

🇺🇸

Raytown, Missouri, United States

Bausch Site 407

🇺🇸

Saint Louis, Missouri, United States

Bausch Site 418

🇺🇸

Warrensburg, Missouri, United States

Bausch Site 424

🇺🇸

Jamestown, New York, United States

Bausch Site 403

🇺🇸

Vestal, New York, United States

Bausch Site 417

🇺🇸

Raleigh, North Carolina, United States

Bausch Site 411

🇺🇸

Fargo, North Dakota, United States

Bausch Site 423

🇺🇸

Miamisburg, Ohio, United States

Bausch Site 425

🇺🇸

West Chester, Ohio, United States

Bausch Site 428

🇺🇸

Grants Pass, Oregon, United States

Bausch Site 427

🇺🇸

Warwick, Rhode Island, United States

Bausch Site 408

🇺🇸

Memphis, Tennessee, United States

Bausch Site 426

🇺🇸

League City, Texas, United States

Bausch Site 419

🇺🇸

San Diego, California, United States

Bausch Site 414

🇺🇸

Leavenworth, Kansas, United States

Bausch Site 435

🇺🇸

San Francisco, California, United States

Bausch Site 404

🇺🇸

Nashville, Tennessee, United States

Bausch Site 433

🇺🇸

Birmingham, Alabama, United States

Bausch Site 416

🇺🇸

Denver, Colorado, United States

Bausch 410

🇺🇸

Brentwood, Tennessee, United States

Bausch Site 420

🇺🇸

State College, Pennsylvania, United States

Bausch Site 437

🇺🇸

Honolulu, Hawaii, United States

© Copyright 2025. All Rights Reserved by MedPath